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Abstract
Background: Parapneumonic empyema continues to be a disease of significant morbidity and mortality among children despite
recent advances in medical management. To date, only a limited number of studies have assessed the burden of empyema in Asia.
Methods: We surveyed medical records of four representative large pediatric hospitals in China, Korea, Taiwan and Vietnam
using ICD-10 diagnostic codes to identify children <16 years of age hospitalized with empyema or pleural effusion from 1995 to
2005. We also accessed microbiology records of cultured empyema and pleural effusion specimens to describe the trends in
the epidemiology and microbiology of empyema.
Results: During the study period, we identified 1,379 children diagnosed with empyema or pleural effusion (China, n = 461;
Korea, n = 134; Taiwan, n = 119; Vietnam, n = 665). Diagnoses of pleural effusion (n = 1,074) were 3.5 times more common
than of empyema (n = 305), although the relative proportions of empyema and pleural effusion noted in hospital records varied
widely between the four sites, most likely because of marked differences in coding practices. Although pleural effusions were
reported more often than empyema, children with empyema were more likely to have a cultured pathogen. In addition, we found
that median age and gender distribution of children with these conditions were similar across the four countries. Among 1,379
empyema and pleural effusion specimens, 401 (29%) were culture positive. Staphylococcus aureus (n = 126) was the most common
organism isolated, followed by Streptococcus pneumoniae (n = 83), Pseudomonas aeruginosa (n = 37) and Klebsiella (n = 35) and
Acinetobacter species (n = 34).
Conclusion: The age and gender distribution of empyema and pleural effusion in children in these countries are similar to the
US and Western Europe. S. pneumoniae was the second leading bacterial cause of empyema and pleural effusion among Asian
children. The high proportion of culture-negative specimens among patients with pleural effusion or empyema suggests that
culture may not be a sufficiently sensitive diagnostic method to determine etiology in the majority of cases. Future prospective
studies in different countries would benefit from standardized case definitions and coding practices for empyema. In addition,
more sensitive diagnostic methods would improve detection of pathogens and could result in better prevention, treatment and
outcomes of this severe disease.
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Globally, respiratory diseases are a leading cause of mor-
bidity and mortality among both children and adults
[1,2]. In developing countries, children less than 5 years
of age are at high risk for severe, life-threatening disease
associated with bacterial and viral pathogens [3]. Strepto-
coccus pneumoniae is a major respiratory pathogen, and the
spectrum of clinical presentations highly associated with
this pathogen includes bacteremic and non-bacteremic
presentations of pneumonia as well as parapneumonic
effusions or empyema [4,5].
Several studies from developed countries suggest that the
prevalence of empyema and pleural effusion may be
increasing [6-10]. In these countries, pediatric empyema
is often quickly identified and treated promptly with sur-
gical intervention or pharmacologic therapy [11,12]. Nev-
ertheless, empyema is associated with prolonged
hospitalization stays (mean ~7 days) and with a case-
fatality rate of about 5–7% [13]. While predictors of
empyema in hospitalized children are not well-known, it
appears that host factors may play a predisposing role
[14]. In developing countries, severe pneumonia in chil-
dren may be associated with necrotizing changes in a uni-
lateral or bilateral pattern [15,16]. In developing
countries, antecedent conditions such as malnutrition,
measles or infection with antibiotic-resistant organisms
may increase the risk of severe pneumonia accompanied
by empyema [17,18]. In South Korea, the 7-valent conju-
gate pneumococcal vaccine (PCV7) was licensed in 2002
and coverage has reached to ~30% in the infant age group
[19]. In Taiwan, PCV7 was introduced in 2006 and cover-
age is <10%. In both Korea and Taiwan, pneumococcal
polysaccharide vaccines (PPV) are available but uptake
has been low in older children and adults [20]. In China
and Vietnam, the PCV7 has not been licensed (likely to
occur in next 2 years) and uptake of PPV has also been
slow and coverage is low (~1%).
The mean age of children with empyema and pleural effu-
sion in developed country studies is 3–6 years with 50%
to 80% of cases occurring in males [21-23]. In previous
studies, bacterial pathogens that included Staphylococcus
aureus, S. pneumoniae, Streptococcus pyogenes and Haemo-
philus influenzae type b (Hib) were associated with
empyema in children [24,25]. However, an emerging
body of literature now suggests that S. pneumoniae in par-
ticular is a major cause of empyema and that selected sero-
types of pneumococcus may play an important role in this
emerging disease pattern [10].
In the Asia-Pacific region, a limited number of clinical and
laboratory studies suggest that S. pneumoniae may also be
the most common etiologic agent in empyema and pleu-
ral effusion specimens [26-28]. In order to better under-
stand epidemiologic and microbiologic patterns of
empyema and pleural effusion among diverse popula-
tions of Asian children <16 years of age, we undertook a
retrospective review of hospital records in four countries.
Methods
Overview
For this study, we selected four tertiary care medical cent-
ers specializing in treatment of children: Chang Gung
Children's Hospital (Taipei, Taiwan), Beijing Children's
Hospital (Beijing, China); Yonsei University Hospital
(Seoul, Korea) and the National Pediatric Hospital affili-
ated with the Ministry of Health (Hanoi, Vietnam). Each
provided a representative sample of patients treated at
major tertiary care hospitals, maintained patient hospital
discharge and laboratory records in computerized data-
bases, and permitted collaboration with experienced clin-
ical researchers. The study protocol was approved by the
International Vaccine Institute Institutional Review
Board. Local investigators met with hospital clinicians
and microbiologists to assess the extent of their experi-
ence with complicated pneumonia and routine microbi-
ology laboratory practices for pleural fluid specimen
testing. Hospital clinical and microbiology departments
were asked to identify and collect information on clini-
cally-diagnosed empyema. Due to variations in hospital
record availability, the data collection periods varied
somewhat–1995–2004 in China and Korea, 2000–2005
in Taiwan and 1996–2005 in Vietnam.
Laboratory and medical records data collection
In each hospital, data collection for patients with
empyema was restricted to hospitalized patients <16 years
of age. Hospital microbiologists accessed laboratory data-
bases and record books to compile a listing of pleural effu-
sion and empyema specimens that were tested by
microbiologic culture. Collaborating investigators also
reviewed computerized microbiology records for reports
of culture-negative and culture-positive empyema or pleu-
ral effusion specimens and provided lists of organisms
isolated in the specimens. In each study hospital, cultures
for anaerobes were not routinely performed. In addition,
these hospital laboratories did not routinely culture for
fungi, mycobacterium and parasites.
International Classification of Diseases (ICD-10) codes were
used to conduct searches of computerized hospital dis-
charge record databases in each collaborating hospital.
Each hospital's medical records department staff created
discharge record databases to identify patients discharged
with an ICD-10 diagnostic code corresponding to pyotho-
rax with fistula (J86.0), pyothorax without fistula (J86.9)
or pleural effusion (J90). To identify the total number of
hospitalized pneumonia patients, we provided a stand-
ardized listing of etiology-specific and non-specific ICD-9Page 2 of 9
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dential identifying information such as national registra-
tion number, the medical records discharge databases
were transferred to the International Vaccine Institute for
review and analysis.
Data analyses
Where possible for each hospital, demographic and hos-
pitalization characteristics were analyzed to describe epi-
demiologic patterns by age group, date of hospital
discharge, type of specimen collected and organism iso-
lated. However, the data on S. pneumoniae in particular
from Taiwan did not include information such as age and
admission dates. An analysis of specimen collection and
patient discharge dates was performed to assess the sea-
sonal distribution of patients with culture-positive and
culture-negative specimens. Statistical comparisons were
performed to identify significant differences in the distri-
bution of different variables by calculating a 95% confi-
dence interval and a critical ratio (Z) test with P-value
(significance level P < 0.05) for the difference between
two independent proportions.
Results
Hospitalizations for empyema and pleural effusion
From the four study hospitals, this review identified a
total of 1,379 patients diagnosed with empyema or pleu-
ral effusion (Table 1): 665 in Vietnam, 461 in China, 134
in Korea and 119 in Taiwan. The number of hospitaliza-
tions due to empyema and pleural effusion increased over
time, at least up to 2002, with some yearly fluctuations.
However, there was no significant change over time in
number of hospitalizations due to empyema and pleural
effusion among the four study hospitals. Overall in the
four countries, 60% of patients with empyema and pleu-
ral effusion were male. A preponderance of males was
noted in all countries (62% in China and Korea and 57%
in Taiwan and Vietnam).
Among the 1,379 patients, 305 (22%) were diagnosed
with empyema and 1,074 (78%) with pleural effusion
(Table 2). In China, all patients were recorded as having
pleural effusion. In Vietnam and Korea, children with
pleural effusion outnumbered those classified with
empyema; 4 to 1 in Vietnam and 2 to 1 in Korea. Hospi-
talization data from Taiwan showed the lowest frequency
of children with pleural effusion – only 4%, while 96%
were coded as empyema. To put our results for empyema
and pleural effusion in context, we identified the total
number of hospitalizations for pneumonia among chil-
dren <15 years of age in each hospital. The Vietnam study
hospital had the most pneumonia hospitalizations (n =
54,673) followed by 14,770, 12,254 and 11,193 in the
China, Taiwan and Korea study hospitals, respectively.
Among these pneumonia hospitalizations, empyema and
pleural effusion were most commonly identified in China
(3.1%) followed by Vietnam and Korea (1.2% each) and
Taiwan (1.0%).
Overall, 21% of all patients diagnosed with empyema or
pleural effusion in the four study hospitals were less than
1 year of age (Table 2). The Vietnam study hospital had
the highest proportion of patients (29%) with empyema
and pleural effusion in that age group followed by Korea
(24%) and China and Taiwan (12% each). Children with
pleural effusions in Korea and Vietnam were significantly
younger than in China (P < .0001). Notably, although the
relative proportion of patients classified with empyema or
pleural effusion was markedly different in China and Tai-
wan, nonetheless the proportion of patients (12%) less
than 1 year of age was identical. The mean age of children
with empyema and pleural effusion in China was 7.6
years compared with 5.1, 4.1 and 3.2 years in Vietnam,
Taiwan and Korea, respectively.
There was no obvious seasonality in the occurrence of
pleural effusion and empyema or in pneumococcal
Table 1: Distribution of patients with empyema or pleural effusion during hospitalization in four hospitals in China, Korea, Taiwan and 
Vietnam, 1995–2005.
Time Period Hospital Location Total
Vietnam* China† Korea† Taiwan‡
1995–1996 48 (7%) 76 (16%) 19 (14%) -- 143 (10%)
1997–1998 113 (17) 114 (25) 7 (5) -- 234 (17)
1999–2000 146 (22) 71 (15) 31 (23) 18 (15) 266 (19)
2001–2002 179 (27) 83 (18) 35 (26) 51 (43) 348 (25)
2003–2005 179 (27) 117 (25) 42 (31) 50 (42) 388 (28)
Total 665 (100) 461 (100) 134 (100) 119 (100) 1,379 (100)
*Vietnam hospital data were available for 10 years (1996–2005).
†China and Korea hospital data were available for 10 years (1995–2004).
‡Taiwan hospital data were only available for 6 years (2000–2005).Page 3 of 9
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empyema and pleural effusion were more likely to be hos-
pitalized in China during the months of May, June and
December (Figure 1), while in Korea, more hospitaliza-
tions occurred during May, July and October. In Vietnam,
June and September were the most common months for
hospitalizations for empyema and pleural effusion.
Culture-positive and culture-negative pleural fluid and 
empyema specimens
A total of 1,379 empyema (n = 310) and pleural effusion
(n = 1,069) specimens were tested by bacterial culture,
and 71% (n = 980) were negative for any bacterial organ-
ism (Table 3). Ninety-two percent of Chinese specimens
tested negative compared with 75% that were culture-neg-
ative in Vietnam, 28% in Taiwan and 19% in Korea.
Among the 310 empyema specimens, 61% (n = 188) were
culture-positive compared with 20% (n = 211) of pleural
effusion specimens that were culture-positive (P < 0.05).
If the 211 children with culture-positive pleural effusion
specimens are grouped into the empyema category, the
percentage of culture-positive specimens increased from
61% to 72% (P < 0.05).
S. aureus was the most common organism isolated in
Korea and Vietnam (29% and 48%, of all positive bacte-
rial isolates, respectively), while S. pneumoniae predomi-
nated in Taiwan (77% of all positive bacterial isolates)
(Table 4). No single pathogen dominated among the few
culture-positive samples from China. Acinetobacter and
Pseudomonas organisms was the 2nd and 3rd most common
pathogens reported in Korea (28% and 11% of all positive
bacterial isolates, respectively), followed by S. pneumoniae
(8% of all positive bacterial isolates). In Vietnam, Kleb-
siella and Pseudomonas species were isolated in 17% and
11% of all positive bacterial isolates. S. pneumoniae was
isolated from 83 patients including 66 (80%) in Taiwan,
9 (11%) in Korea, 5 (6%) in China and 3 (3%) in Viet-
nam. Of the 83 pneumococcal isolates, 82% (n = 68) were
from empyema cases, mostly from Taiwan, compared to
18% (n = 15) from pleural effusion cases.
Discussion
Our study results show that pleural effusion and
empyema occur in Asia among young children at rates
similar to those observed elsewhere (1–3% of pneumonia
admissions) [29-31]. However, the clinical differentiation
between pleural effusion and empyema may be inter-
preted differently from one country to another, as sug-
gested by the great difference in the proportion of the two
types reported in the four countries studied. For example,
in China, 100% of the pleural effusion and empyema
cases were coded only as pleural effusion, but it is likely
that these included many empyema cases. In contrast, in
Taiwan, only 4% of the cases were coded as pleural effu-
sion, suggesting either that virtually no pleural fluid sam-
ples were taken from children diagnosed with
uncomplicated pleural effusions or that all patients from
whom samples are taken are automatically coded as
"empyema". In Korea and Vietnam, the proportions were
more mixed, but coding for pleural effusion nonetheless
predominated. Regardless of the distinction, these find-
Table 2: Age distribution of hospitalized children with empyema and pleural effusion in China, Korea, Taiwan and Vietnam.
Age group Vietnam N (%) China N (%) Korea N (%) Taiwan N (%) Total N (%)
Empyema Pleural effusion Empyema Pleural effusion Empyema Pleural effusion Empyema Pleural effusion
1 50 (35.7) 140 (26.7) -- 56 (12.1) 6 (11.8) 26 (31.3) 13 (11.4) 1 (20.0) 292 (21.2)
2 31 (22.1) 64 (12.2) -- 25 (5.4) 16 (31.4) 17 (20.5) 8 (7.0) 1 (20.0) 162 (11.7)
3 15 (10.7) 32 (6.1) -- 21 (4.6) 7 (13.7) 12 (14.5) 19 (16.7) 0 (0) 106 (7.7)
4 14 (10.0) 30 (5.7) -- 23 (5.0) 1 (2.0) 4 (4.8) 20 (17.5) 1 (20.0) 93 (6.7)
5 5 (3.6) 28 (5.3) -- 31 (6.7) 2 (3.9) 5 (6.0) 24 (21.1) 0 (0) 95 (6.9)
6 2 (1.4) 12 (2.3) -- 36 (7.8) 5 (9.8) 0 (0) 11 (9.6) 0 (0) 66 (4.8)
7 2 (1.4) 21 (4.0) -- 41 (8.9) 0 (0) 1 (1.2) 9 (7.9) 0 (0) 74 (5.4)
8 3 (2.1) 18 (3.4) -- 48 (10.4) 3 (5.9) 0 (0) 3 (2.6) 0 (0) 75 (5.4)
9 2 (1.4) 25 (4.8) -- 35 (7.6) 1 (2.0) 5 (6.0) 0 (0) 1 (20.0) 69 (5.0)
10 4 (2.9) 36 (6.9) -- 35 (7.6) 2 (3.9) 2 (2.4) 1 (0.9) 0 (0) 80 (5.8)
11 2 (1.4) 20 (3.8) -- 22 (4.8) 0 (0) 0 (0) 1 (0.9) 0 (0) 45 (3.3)
12 6 (4.3) 34 (6.5) -- 24 (5.2) 2 (3.9) 1 (1.2) 1 (0.9) 0 (0) 68 (4.9)
13 1 (0.7) 27 (5.1) -- 36 (7.8) 1 (2.0) 0 (0) 2 (1.8) 1 (20.0) 68 (4.9)
14 1 (0.7) 22 (4.2) -- 23 (5.0) 3 (5.9) 6 (7.2) 0 (00) 0 (0) 55 (4.0)
15 2 (1.4) 16 (3.0) -- 5 (1.1) 2 (3.9) 4 (4.8) 2 (1.8) 0 (0) 31 (2.2)
Total 140 (100) 525 (100) -- 461 (100) 51 (100) 83 (100) 114 (100) 5 (100) 1,379 (100)
NOTE. Data for China and Korea are for 1995–2004; for Taiwan, 2000–2005; and Vietnam, 1996–2005.
NOTE: Specimen type in China was not stratified by appearance.Page 4 of 9
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Monthly distribution of microbiologic culture results from testing of empyema and pleural fluid specimens in China, Korea and Vietnam *F gure 1
Monthly distribution of microbiologic culture results from testing of empyema and pleural fluid specimens in 
China, Korea and Vietnam.* *China and Korea (1995 to 2004); Taiwan (2000 to 2005) and Vietnam (1996 to 2005).
BMC Infectious Diseases 2008, 8:90 http://www.biomedcentral.com/1471-2334/8/90ings emphasize the importance of looking at coding for
both pleural effusion and empyema in order to under-
stand the epidemiology of complicated pneumonias.
In this review, one-third of the empyema patients identi-
fied were less than 2 years of age confirming that
empyema may be more likely to occur in young children
than in older children. In India, one-third of hospitalized
children with empyema were <5 years of age [26]. The
mean age (4~5 years) of children with empyema and
pleural effusion in our study was similar to findings else-
where [32-34].
The absence of a distinct seasonality in the distribution of
empyema patients in this study suggests weather may not
be an important contributing factor or that the etiologic
agents of empyema and pleural effusions specimens could
be a heterogeneous group of infectious agents. This con-
clusion is supported, in part, by data from microbiologic
cultures of empyema and pleural fluid showing a wide
Table 3: Organisms identified in empyema and pleural effusion specimens from China, Korea, Taiwan and Vietnam, 1995–2005.
Cultured Organism Empyema N (%) Pleural effusion N (%) Total N (%)
Culture negative 122 (39) 858 (80) 980 (71)
Gram negative 51 (17) 104 (10) 155 (11)
Gram positive
S. pneumoniae 68 (22) 15 (1) 83 (6)
Others 69 (22) 92 (9) 161 (12)
Total 310 (100) 1,069 (100) 1,379 (100)
Table 4: Distribution of isolates in empyema and pleural effusion specimens by country.
Empyema or Pleural Fluid Isolates Vietnam China Korea Taiwan Total
(n = 665) (n = 461) (n = 134) (n = 119) (n = 1,379)
Culture negative 496 (74.6) 424 (92.0) 25 (18.7) 33 (27.7) 978 (70.9)
Staphylococcus aureus 81 (12.2) 7 (1.5) 32 (23.9) 6 (5.0) 126 (9.1)
Streptococcus pneumoniae 3 (0.5) 5 (1.1) 9 (6.7) 66 (55.5) 83 (6.0)
Pseudomonas aeruginosa 19 (2.9) 5 (1.1) 12 (9.0) 1 (0.8) 37 (2.7)
Klebsiella spp. 28 (4.2) 4 (0.9) 3 (2.2) 0 (0) 35 (2.5)
Acinetobacter spp. 4 (0.6) 0 (0) 30 (22.4) 0 (0) 34 (2.5)
Escherichia coli 9 (1.4) 1 (0.2) 2 (1.5) 1 (0.8) 13 (0.9)
Enterococcus spp. 2 (0.3) 1 (0.2) 8 (6.0) 0 (0) 11 (0.8)
Haemophilus influenzae type b 9 (1.4) 0 (0) 1 (0.7) 4 (3.4) 14 (1.0)
Enterobacter spp. 1 (0.2) 2 (0.4) 6 (4.5) 0 (0) 9 (0.7)
Streptococcus spp. 8 (1.2) 0 (0) 1 (0.7) 1 (0.8) 10 (0.7)
Stenotrophomonas maltophilia 0 (0) 1 (0.2) 3 (2.2) 0 (0) 4 (0.3)
Mycoplasma pneumoniae 0 (0) 0 (0) 0 (0) 4 (3.4) 4 (0.3)
Corynebacterium spp. 0 (0) 2 (0.4) 0 (0) 0 (0) 2 (0.2)
Candida albicans 2 (0.3) 0 (0) 1 (0.7) 0 (0) 3 (0.2)
Citrobacter spp. 2 (0.3) 0 (0) 0 (0) 0 (0) 2 (0.2)
Fungi 0 (0) 2 (0.5) 0 (0) 0 (0) 2 (0.2)
Micrococcus spp. 0 (0) 2 (0.4) 0 (0) 0 (0) 2 (0.2)
Burkholderia cepacia 0 (0) 0 (0) 1 (0.7) 0 (0) 1 (0.1)
Haemophilus parainfluenzae 0 (0) 1 (0.2) 0 (0) 0 (0) 1 (0.1)
Anaerobic 1 (0.2) 0 (0) 0 (0) 0 (0) 1 (0.1)
Neisseria spp. 0 (0) 1 (0.2) 0 (0) 0 (0) 1 (0.1)
Staphylococcus epidermidis 0 (0) 1 (.02) 0 (0) 0 (0) 1 (0.1)
Staphylococcus intermedius 0 (0) 1 (0.2) 0 (0) 0 (0) 1 (0.1)
viridans group streptococci 0 (0) 1 (0.2) 0 (0) 0 (0) 1 (0.1)
Veillonella spp. 0 (0) 0 (0) 0 (0) 1 (0.8) 1 (0.1)
Clostridium spp. 0 (0) 0 (0) 0 (0) 1 (0.8) 1 (0.1)
Prevotella spp. 0 (0) 0 (0) 0 (0) 1 (0.8) 1 (0.1)
Total 665 (100) 461 (100) 134 (100) 119 (100) 1,379 (100)Page 6 of 9
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well as fungi and culture-negative specimens.
Our study identified several children whose empyema or
pleural fluid cultures grew bacterial pathogens normally
associated with community-acquired lower respiratory
tract disease including Hib, S. pneumoniae and S. aureus
[35-37]. These findings are consistent with a growing
number of reports suggesting that much childhood
empyema could be vaccine-preventable [38,39]. In our
study hospitals, data on bacterial species also suggest
either that a large proportion of children may acquire
Gram-negative pathogens as nosocomial infections or
that a number of bacterial isolates are contaminants of
laboratory cultures [40,41]. Previous reviews or case series
describing bacterial organisms isolated from children
with empyema suggest that Gram-positive as well as
Gram-negative organisms may invade the pleural space
[42,43].
In our study, a high proportion (71%) of all empyema
and pleural fluid specimens grew no bacterial pathogen.
This finding is consistent with a number of previous stud-
ies suggesting that the negative cultures are not the result
of limitations in routine microbiology laboratory proce-
dures. The negative cultures more likely are due to the
widespread use of antibiotics (including inappropriately
chosen or dosed antibiotics) as well the potential for
severe viral lower respiratory tract disease to be associated
with pleural effusion or bacterial superinfections resulting
in necrotizing pneumonia and empyema [44,45]. This
study collected data from existing computerized hospital
discharge databases and laboratory records but individual
patient medical records were not accessed to obtain infor-
mation on prior treatment with antibiotics. In general, in
our previous studies, we have found that parent- or
patient-reported prior use of antibiotics is often not
recorded in medical records. In addition, the high rate of
negative cultures may be due to the presence of fastidious
organisms such as anaerobic bacteria [46]. Based on our
previous studies in Asia, we have found that many hospi-
tal laboratories do not use anaerobic culture media.
According to a recent study reported by Song JH et al, the
prevalence of penicillin resistance in S. pneumoniae iso-
lates was 71.4% in Vietnam followed by Korea (54.8%),
Taiwan (38.6%) and China (23.4%) [47]. Given the high
proportion of bacterial culture-negative pleural fluid spec-
imens, a more complete assessment of parapneumonic
pleural effusions or empyema in prospective studies could
apply non-culture-based antigen detection or polymerase
chain reaction tests to detect both bacterial and viral path-
ogens. These tests have been used to identify children with
culture-negative pneumococcal infections [43,48-50].
These sensitive diagnostic tools can help us to better
understand the burden of disease, trends over time, epide-
miological differences among countries, patient demogra-
phy, symptomatology, etiological agents and rational
treatment. Unfortunately, at present, these laboratory
techniques are only generally available in research labora-
tories.
A number of investigators have shown that laboratory
testing of pleural fluid or empyema specimens in children
with pneumonia can provide important insights into the
origins of the pneumonia [51,52]. In Asia relatively few
children hospitalized with serious pneumonia undergo
thoracocentesis diagnostic procedures to identify patho-
gens in pleural or empyema fluid, which are relatively less
culturally acceptable in Asian populations [53]. Neverthe-
less, given the number of children identified in our retro-
spective survey, prospective multi-center studies in Asia
are likely to yield substantial numbers of patients with
empyema or complicated pleural effusions and shed light
on the etiological agent associated with parapneumonic
empyema and pleural effusions.
In this study, we found that children with empyema were
significantly more likely to have positive bacterial cultures
compared with children in whom pleural effusion speci-
mens were collected. These data are consistent with previ-
ous studies suggesting that empyema fluid is the result of
established infections and inflammatory reactions
[28,54]. However, given the fact that clinicians in Asia
have also found it necessary to collect clinical specimens
from patients with pleural effusions, it is likely that pro-
spective studies that include an evaluation of bacterial
pathogens in pleural effusions specimens will yield a
more accurate picture of the total burden of disease asso-
ciated with invasive bacterial pneumonia and parapneu-
monic bacterial infections.
This study has some limitations. First, as a retrospective
review, our data collection, analysis and reporting were
restricted to that available in hospital databases or log-
books. Thus, for some years of data, incomplete patient
information precluded further analysis. Computerized
hospital administrative databases were accessed by collab-
orating study investigators. Nevertheless, in some hospi-
tals we found that current levels of data entry limited the
amount of clinical and historical data available. The
increasing use of electronic medical records in Asia sug-
gests that additional patient clinical and laboratory data
are likely to be available in a number of countries in com-
ing years. Finally, because the hospitals in our review did
not record more than one ICD-10 diagnostic code, we
were unable to determine other clinical conditions that
the children may have had at the time of their hospitaliza-
tion and thus we could not determine the proportion of
children with pneumonia or lower respiratory tract infec-Page 7 of 9
(page number not for citation purposes)
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specimens collected.
Similarly, as the hospital laboratories did only limited
testing, there was no means to identify underlying causes
of lower respiratory tract disease in infants and young
children. In addition, most clinical laboratories in the
study countries do not routinely preserve bacterial isolates
from pleural fluid specimens because they lack resources
and awareness of the utility of such specimens for research
and advancement of treatment.
Conclusion
Future incidence studies in such hospitals to determine
the true burden of parapneumonic empyema may be fea-
sible if catchment areas for study sites can be well-defined.
Recent studies from France [42,55] suggest that the inci-
dence of empyema may vary over time. Our results suggest
that prospective surveillance for pneumonia with
empyema or pleural effusions could be established as part
of larger surveillance for severe bacterial infections includ-
ing meningitis and sepsis. Surveillance for invasive bacte-
rial diseases can be improved by: a) applying standardized
case definitions; b) create, disseminate and implement
standard pediatric guidelines for treatment of pneumonia,
empyema and other syndromes associated with invasive
bacterial diseases; c) requiring report of clinical laboratory
specimens from normally sterile sites that are culture-pos-
itive for Hib, S. pneumoniae, N. meningitidis and other
invasive bacterial pathogens; and d) implementing stand-
ard operating procedures that maximize capacity for
detection of invasive bacterial pathogens in hospital labo-
ratories. Future prospective studies of empyema will ben-
efit from standardized case definitions and coding
practices for empyema as well as pleural effusion.
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